The latest price trends of lenvatinib/lenvatinib in 2025

Lenvatinib is a multi-target oral tyrosine kinase inhibitor (TKI) developed by Eisai of Japan. It is used to treat a variety of malignant tumors, including advanced renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and combination immunotherapy for certain types of endometrial cancer. With its widespread use in clinical practice, price and accessibility have become one of the topics of greatest concern to patients.

Currently, lenvatinib has been officially launched in China and has been included in the national medical insurance directory, which means that its economic burden is greatly reduced compared with the past. According to the latest market conditions in the domestic market, the price of lenvatinib in a 4 mg*30 capsule format is approximately 3,000 yuan. Since medical insurance policies vary slightly from region to region, the actual amount paid by the patient depends on the local medical insurance reimbursement ratio and hospital pricing. Compared with the price of tens of thousands of yuan in the initial stage of the market, now that it is included in medical insurance, the affordability of the drug has been significantly improved, which has also promoted the increase in the clinical use of the drug.

In the international market, the price of lenvatinib varies between countries and drug channels. The price of original research drugs sold in Japan and Europe is relatively stable, equivalent to about RMB 2,000 per box. In some developing countries, prices have dropped significantly as generic drugs have been approved for marketing. The generic version of lenvatinib mainly comes from Bangladesh and Laos. The active ingredients, dosage design and dissolution characteristics of the drugs produced by local pharmaceutical companies after the patent expiration or licensing are consistent with the original drugs.

For example, the Bangladeshi versionThe price of generic Lenvatinib is between RMB 400 and RMB 900. The price of the Laos version is slightly lower, but the total price still fluctuates due to factors such as export, transportation and exchange rate changes. These generic drugs have obtained registration approval in the drug regulatory systems of some countries and are used to assist patients in reducing treatment costs. For patients with limited financial conditions or who cannot be reimbursed by medical insurance, generic drugs have become a cost-effective option.

Reference materials:https://www.lenvima.com/